CASI Pharmaceuticals, Inc. (CASIF) stock
CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
$0.10+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
CASI Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $6.31M, down 29.3% from the year before. The highest annual figure on record is $16.00M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.31M | -29.3% |
| FY2024 | Dec 31, 2024 | $8.92M | -9.6% |
| FY2023 | Dec 31, 2023 | $9.86M | -38.4% |
| FY2022 | Dec 31, 2022 | $16.00M | +10.9% |
| FY2021 | Dec 31, 2021 | $14.42M | +25.7% |
| FY2020 | Dec 31, 2020 | $11.47M | – |
See a number that looks wrong?